Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.

You may also be interested in...

FDA Warning Letter Is Inadmissible Hearsay, Arkansas Supreme Court Says In Tossing J&J Judgment

Court throws out $1.2 billion award to the state of Arkansas over Risperdal promotions.

NICE Appraisal Strikes Down Three Ovarian Cancer Drugs In The U.K.

As the result of a multiple technology appraisal from Britain’s U.K.’s reimbursement watchdog, NICE, three ovarian cancer drugs will disappear from the publicly funded NHS.

Risperdal Marketing Settlement Prevents Reprint Distribution Without sNDA

J&J’s agreement with state AGs, which involves payments totaling $181 million, sets a number of restrictions on the company’s marketing practices for atypical antipsychotics that will be in effect for five years.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts